About Bio-Path
Paving the way for revolutionary treatment of disease
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients, who are not eligible for or who have decided to forego intensive chemotherapy because of their fragile health, and in refractory/relapsed AML patients. Additionally, BP1001-A is being assessed in a Phase 1 study in refractory/relapsed patients with solid tumors. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in patients with refractory/relapsed lymphoma and AML.
A Gentler Path
AML incidence increases with age, with more than 50% of the cases in people age 60 or older. Prognosis for elderly AML patients remains very poor. The cure rate is between 5-15% in older adults, and those who cannot receive the standard course of high dose chemotherapy have an average survival rate of five to ten months. This is clearly a disease with a high unmet medical need. Prexigebersen, Bio-Path’s AML drug candidate, blocks the production of Grb2, a protein that is essential in regulating the proliferation and chemosensitivity of cancer cells. Inactivation of Grb2 has been shown to halt cancer cell proliferation and enhance the anticancer activity of chemotherapeutic agents.
Non-Hodgkin’s lymphoma (NHL) can start anywhere in the body where lymph tissue is found. Approximately 60% of NHLs are aggressive lymphomas that need to be treated right away, as they can grow and spread quickly to other parts of the lymph system or to other parts of the body. BP1002, our second drug candidate, targets the Bcl-2 protein, which is responsible for driving cancer cell survival. BP1002 is intended to target refractory/relapsed lymphoma, chronic lymphocytic leukemia, and AML. Inhibition of Bcl-2 has been shown to enhance the anticancer activity of chemotherapeutic agents and cancer cell death.
The Heart of Houston
Bio-Path is located in the heart of Houston, on the edge of the Texas Medical Center campus, which is home to leaders in research, medicine, and innovation in healthcare. Bio-Path was founded with technology licensed from The University of Texas MD Anderson Cancer Center. The Company has since developed its own patented technology, with intellectual property solely owned by the Company that includes composition of matter and method patents for liposomal antisense DNA targets and manufacturing that enables systemic delivery of antisense drugs through a patient’s vascular system. Bio-Path maintains strong working relationships with several cancer research centers.
Bio-Path Holdings is actively developing new targets for hematopoietic diseases and solid tumors and collaborates with academic and clinical leaders to build programs in and beyond oncology.
